U.S. patent application number 13/911135 was filed with the patent office on 2013-12-19 for implantation of micronized allograft tissue over a microfractured defect.
The applicant listed for this patent is Arthrex, Inc.. Invention is credited to Robert Benedict, James P. Bradley, Brian J. Cole, James L. Cook, Lisa A. Fortier, Eric Giza, G. Joshua Karnes, Brandon L. Roller, Tithi Dutta Roy, Reinhold Schmieding, David O. Shepard.
Application Number | 20130338792 13/911135 |
Document ID | / |
Family ID | 49756614 |
Filed Date | 2013-12-19 |
United States Patent
Application |
20130338792 |
Kind Code |
A1 |
Schmieding; Reinhold ; et
al. |
December 19, 2013 |
IMPLANTATION OF MICRONIZED ALLOGRAFT TISSUE OVER A MICROFRACTURED
DEFECT
Abstract
Techniques, mixtures, mixing and delivery kits, and improved
delivery instruments for implantation of micronized allograft
tissue over a microfractured defect. Allograft cartilage tissue is
delivered over a cartilage defect that has been debrided and
microfractured, without the need for a periosteal covering or
separate type of patch sewn over the top. The allograft tissue may
be any micronized cartilage particulates obtained by various
methods, for example, cartilage delivered in its native form,
dehydrated via lyophilization, "freeze-dried," dehydrated via
desiccation, or dehydrated by any other method.
Inventors: |
Schmieding; Reinhold;
(Naples, FL) ; Roller; Brandon L.; (Naples,
FL) ; Shepard; David O.; (Naples, FL) ;
Karnes; G. Joshua; (Estero, FL) ; Benedict;
Robert; (Fort Myers, FL) ; Roy; Tithi Dutta;
(Estero, FL) ; Cole; Brian J.; (Chicago, IL)
; Bradley; James P.; (Pittsburgh, PA) ; Giza;
Eric; (Carmichael, CA) ; Cook; James L.;
(Columbia, MO) ; Fortier; Lisa A.; (Syracuse,
NY) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Arthrex, Inc. |
Naples |
FL |
US |
|
|
Family ID: |
49756614 |
Appl. No.: |
13/911135 |
Filed: |
June 6, 2013 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61660351 |
Jun 15, 2012 |
|
|
|
Current U.S.
Class: |
623/23.73 |
Current CPC
Class: |
A61F 2002/30588
20130101; A61F 2/30756 20130101; A61L 27/3604 20130101; A61L
27/3612 20130101; A61L 27/3616 20130101; A61F 2/4618 20130101; A61L
27/3834 20130101 |
Class at
Publication: |
623/23.73 |
International
Class: |
A61F 2/30 20060101
A61F002/30 |
Claims
1. A method of surgery consisting essentially of the steps of:
conducting microfracture surgery to obtain a microfracture site;
and providing a micronized allograft mixture at the microfracture
site, the micronized allograft mixture comprising micronized
allograft tissue particles and an autologous blood product.
2. The method of claim 1, wherein the micronized allograft tissue
particles have a size of about 0-300 microns.
3. The method of claim 1, further comprising the step of applying a
layer of fibrin over the micronized allograft mixture at the
microfracture site.
4. The method of claim 1, wherein the micronized allograft tissue
particles are desiccated cartilage particles.
5. The method of claim 1, wherein the micronized allograft mixture
consists essentially of micronized allograft tissue particles and
autologous blood product.
6. The method of claim 1, wherein the autologous blood product is
selected from the group consisting of whole blood, autologous
conditioned plasma, platelet-rich plasma, bone marrow aspirate,
bone marrow concentrate, and stem cells.
7. The method of claim 1, wherein the micronized allograft mixture
is formed by the steps of: providing a syringe comprising a tube
and a plunger that fits tightly in the tube, the plunger being
formed of a pushrod and a mixing element attached to the pushrod,
the pushrod fitting into the mixing element and being designed to
unsnap from the mixing element and snap back into the mixing
element; bringing together micronized allograft tissue particles
and autologous blood product into the tube; removing the pushrod
from the mixing element; and moving the mixing element in at least
one direction to mix the micronized allograft tissue particles with
the autologous blood product and to obtain the micronized allograft
mixture.
8. The method of claim 1, wherein the micronized allograft mixture
further comprises growth factors, antiseptics, antibiotics,
electrolytes and stem cells.
9. The method of claim 1, wherein the microfracture site is part of
a cartilage surface.
10. The method of claim 9, wherein the microfracture site is part
of a knee, an ankle, a foot, a shoulder, a hand, a wrist, an elbow,
or a hip.
11. A method of articular cartilage repair, comprising the steps
of: preparing a cartilage defect by microfracture surgery;
preparing a micronized cartilage paste with particles size of about
0-300 microns, the micronized cartilage paste consisting
essentially of micronized cartilage particulates and autologous
blood product; and applying the micronized cartilage paste over the
cartilage defect without the need of applying a covering over the
cartilage defect.
12. The method of claim 11, wherein the micronized cartilage
particulates are obtained by dehydration of cartilage via
desiccation.
13. The method of claim 11, wherein the micronized cartilage
particulates are obtained by dehydration of cartilage via
desiccation or lyophilization.
14. The method of claim 11, further comprising the step of adding,
to the micronized cartilage paste, a component selected from the
group consisting of growth factors, antiseptics, antibiotics,
electrolytes and stem cells.
15. The method of claim 11, wherein the micronized cartilage paste
is formed by: providing micronized cartilage particulates together
with autologous blood product in a syringe comprising a tube and a
plunger that fits tightly in the tube, the plunger being formed of
a pushrod and a mixing element attached to the pushrod, the pushrod
fitting into the mixing element and being designed to engage and
disengage the mixing element; and disengaging the pushrod from the
mixing element to allow the mixing element to move in at least two
different directions to allow mixing of the micronized cartilage
particulates with the autologous blood product in the tube to form
the micronized cartilage paste.
16. A graft for treatment of a microfracture site, the graft
comprising a biological allograft mixture consisting essentially of
morselized, freeze-dried or desiccated cartilage and an autologous
blood product.
17. The graft of claim 16, wherein the autologous blood product is
blood, platelet-rich plasma, autologous conditioned plasma, bone
marrow aspirate, bone marrow concentrate, stem cells, or
combinations thereof.
18. The graft of claim 16, wherein the graft further includes
growth factors, antiseptics, antibiotics and electrolytes.
19. The graft of claim 16, wherein the microfracture site is part
of a cartilage surface.
20. The graft of claim 19, wherein the cartilage surface is part of
a knee, an ankle, a foot, a shoulder, a hand, a wrist, an elbow, or
a hip.
21. A kit for mixing and delivering a micronized allograft paste to
repair a microfracture site of a cartilage defect, comprising: a
mixing syringe comprising a tube and a plunger consisting of a
pushrod and a mixing element, wherein the pushrod is configured to
engage and disengage the mixing element; at least one straight
needle; at least one curved needle; and an obturator.
22. The kit of claim 21, wherein the kit comprises one straight
needle and a 45 degree delivery needle.
23. The kit of claim 21, further comprising a funnel for delivery
of micronized allograft particles into the tube.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional
Application No. 61/660,351 filed Jun. 15, 2012, the disclosure of
which is incorporated by reference in its entirety herein.
FIELD OF THE INVENTION
[0002] The present invention relates to the field of surgery and,
more particularly, to improved technologies for allograft cartilage
repairs.
BACKGROUND OF THE INVENTION
[0003] Articular cartilage injuries affect approximately 900,000
individuals in the United States every year. Numerous surgical
interventions exist which focus on inciting cartilage repair
including debridement and chondroplasty, microfracture,
osteochondral allograft transplantation, and autologous chondrocyte
implantation (ACI). These techniques have varying levels of
success, with the ultimate goal being to generate hyaline cartilage
in the defect, to recreate normal articular congruity, and to
improve overall functioning, disability and health. Of these
various techniques, microfracture is the most commonly
utilized.
[0004] The microfracture procedure is a form of bone-marrow
stimulation which enhances cartilage repair by taking advantage of
the body's own healing potential. A sharp awl (i.e., a pick) is
used arthroscopically through one of the arthroscopic skin portals
and a mallet is used to impact the awl into the subchondral bone
and thus generate bleeding from the bone. Holes are created at
regular intervals until the entire defect has been addressed. The
penetration of the subchondral bone allows for the communication of
the osteochondral defect with mesenchymal stem cells and growth
factors from the bone marrow and eventually leads to the formation
of fibrocartilagenous tissue that covers the cartilage lesion.
[0005] Microfracture is typically performed by arthroscopy, after
the joint is cleaned of calcified cartilage. Through use of an awl,
the surgeon creates tiny fractures in the subchondral bone plate.
Blood and bone marrow (which contains stem cells) seep out of the
fractures, creating a blood clot over the defect. The stem cells
from the bone marrow and from the underlying subchondral bone
interact with the clot and use this as the initial scaffold to
begin the process of cellular differentiation into fibrocartilage
or cartilage-building cells. The microfractures are treated as an
injury by the body, which is why the surgery results in new,
replacement tissue. The procedure is effective in gaining a
combination of fibrocartilage and hyaline cartilage (which are not
formed from an osteochondritis dissecan (OC) defect alone).
[0006] Although good results have been achieved with microfracture
treatments, some studies have concluded that, while microfracture
provides effective short-term functional improvement of knee
function, there is insufficient data on its long-term results.
Additional shortcomings of the technique include limited hyaline
repair tissue, variable repair cartilage volume, and possible
functional deterioration over time.
[0007] A recent technology used to augment the microfracture
technique is through the use of an allograft extracellular matrix.
BioCartilage.RTM. is an example of desiccated micronized cartilage
extracellular matrix tissue allograft that has been developed for
ICRS grade III or greater articular cartilage lesions in
conjunction with microfracture.
[0008] BioCartilage.RTM. is developed from allograft cartilage that
has been dehydrated and micronized. BioCartilage.RTM. contains the
extracellular matrix that is native to articular cartilage
including key components such as type II collagen, proteoglycans,
and additional cartilaginous growth factors. The principle of
BioCartilage.RTM. is to serve as a scaffold over a microfractured
defect providing a tissue network that can potentially signal
autologous cellular interactions and improve the degree and quality
of tissue healing within a properly prepared articular cartilage
defect.
[0009] This allograft tissue is combined with platelet-rich plasma
and the resultant solution is added to a microfractured chondral
lesion and "fixed" with a fibrin coverage. The addition of
platelet-rich plasma (PRP) to the dessicated BioCartilage.RTM.
scaffold is considered a beneficial addition due to the anabolic
and anti-inflammatory factors associated with PRP. The added fibrin
content in PRP provides additional structure to the final matrix
pre and post implantation.
[0010] A need exists for techniques that allow delivery of
allograft cartilage tissue over a cartilage defect that has been
debrided and microfractured, without the need for a periosteal
covering or separate type of patch sewn over the top. Also needed
are methods and special delivery instruments for rebuilding a
defective cartilage in difficult-to-reach areas such as the ankle.
An augmented microfracture procedure that addresses sub-chondral
lesions is also needed.
BRIEF SUMMARY OF THE. INVENTION
[0011] The present invention provides techniques, mixtures, mixing
and delivery kits, and improved delivery instrumentation for
implantation of micronized allograft tissue over a microfractured
defect. Micronized allograft tissue is delivered over a cartilage
defect that has been debrided and microfractured, without the need
for a periosteal covering or separate type of patch sewn over the
top.
[0012] The allograft tissue may consist of any micronized cartilage
particulates obtained by various methods, for example, cartilage
delivered in its native form, dehydrated via lyophilization,
"freeze-dried," dehydrated via desiccation, or dehydrated by any
other method. The micronized cartilage particulates may have a size
of about 0-300 microns.
[0013] The methods of the present invention use allograft material
over a cartilage defect that has been prepared by microfracture
surgery. The mixture of the allograft material has a paste-like
consistency so that it can be conformed to any defect size or
shape, including the ability of the paste-like mixture to be
delivered during an open procedure or arthroscopically. A fibrin
adhesive may be utilized, preferably more as a covering and not
throughout the product. The method of the present invention also
provides formation of micronized particles via the process of
desiccation instead of lyophilization.
[0014] Other features and advantages of the present invention will
become apparent from the following description of the
invention.
BRIEF DESCRIPTION OF THE DRAWINGS
[0015] FIGS. 1-12 illustrate instruments, mixing kits and methods
of forming micronized allograft tissue according to an exemplary
embodiment of the present invention.
[0016] FIGS. 13-16 illustrate instruments, mixing kits and methods
of forming micronized allograft tissue according to another
exemplary embodiment of the present invention.
[0017] FIGS. 17-22 illustrate subsequent steps of a method of
delivering the micronized allograft tissue of FIG. 12 over a
microfractured defect (an exemplary microfractured knee defect)
according to an exemplary embodiment of the present invention.
[0018] FIGS. 23-28 illustrate subsequent steps of a method of
delivering the micronized allograft tissue of FIG. 12 over a
microfractured defect (an exemplary microfractured knee defect)
according to another exemplary embodiment of the present
invention.
[0019] FIGS. 29-34 illustrate subsequent steps of a method of
delivering the micronized allograft tissue of FIG. 12 over a
microfractured defect (an exemplary microfractured ankle defect)
according to another exemplary embodiment of the present
invention.
DETAILED DESCRIPTION OF THE INVENTION
[0020] The present invention provides mixing and delivery
techniques for micronized allograft tissue over a microfractured
defect. The present invention also provides techniques for
implantation of such micronized allograft tissue at a microfracture
site.
[0021] Allograft tissue is delivered over a cartilage defect that
has been debrided and microfractured without the need for a
periosteal covering or separate type of patch sewn over the top.
The allograft tissue may be allograft cartilage in the form of
micronized cartilage particulates which may be cartilage delivered
in its native form, dehydrated via lyophilization, dehydrated via
desiccation, or dehydrated by any other method, among others. The
micronized cartilage particulates may have a size of about 0-300
microns.
[0022] In an exemplary embodiment only and as detailed below,
cartilage with particles of about 0-300 microns is employed to form
a moldable allograft paste (mixture or composition). Preferably,
the moldable allograft paste comprises cartilage in the form of
morsellized, freeze-dried and/or desiccated cartilage. Cartilage
(in the form of morsellized, freeze-dried and/or desiccated
cartilage) may be processed by a tissue bank similar to the
BioCartilage.RTM. process for hyaline cartilage. The sterile,
freeze-dried and/or desiccated product is mixed (by the orthopedic
surgeon, for example) at the time of surgery with autologous blood
or a biologic equivalent to create a moldable allograft paste that
can be delivered (by injection, for example) at the microfracture
site.
[0023] The present invention also provides methods of tissue
repairs of an articular cartilage defect with microfracture and
micronized allograft tissue. An exemplary method of
providing/implanting micronized allograft tissue over a
microfractured defect according to an exemplary embodiment of the
present invention comprises inter alia the steps of: (i) conducting
microfracture surgery to provide a microfracture site at an
articular cartilage defect; (ii) mixing allograft tissue
(cartilage) micronized into particles with a size of about 0-300
.mu.m with an autologous blood product (whole blood, platelet-rich
plasma, autologous conditioned plasma, bone marrow, or stems cells,
among others) in a specially-designed mixing syringe, to obtain a
micronized allograft mixture having a paste-like consistency that
can be injected through a needle or small cannula; and (iii)
delivering the micronized allograft mixture at the microfracture
site (through either an open procedure or an arthroscopic
procedure).
[0024] The present invention also provides methods of preparing a
micronized cartilage mixture. An exemplary method comprises inter
alia the steps of: (i) placing about 1.0 cc of micronized cartilage
(for example, desiccated articular cartilage) into a custom 3 cc
syringe; (ii) using a second syringe which contains about 1.0 cc of
an autologous blood solution and injecting it into the custom
syringe (in a 1:1 ratio); and (iii) mixing the autologous blood
solution with the micronized cartilage in the custom syringe by
using a mixing element which is built into the custom syringe, to
mix the two components/substances together to create a resulting
mixture with a paste-like consistency. The method may further
comprise the step of providing instruments (needles) having curved
or straight configurations (such as a Tuohy-style delivery needle),
particularly for defects in the ankle which are more difficult to
reach. For example, a curved needle (such as, a 10 G Touhy needle)
may be applied to the end of the syringe containing the micronized
cartilage paste, to deliver the paste to the microfracture
defect.
[0025] Referring now to the drawings, where like elements are
designated by like reference numerals, FIGS. 1-16 illustrate
various instruments, mixing and delivery kits, and methods of
forming micronized allograft tissue mixtures (having a paste-like
consistency) to be delivered over a microfractured defect according
to the present invention. FIGS. 17-34 illustrate various methods of
delivering micronized allograft over exemplary microfractured
defects according to the present invention.
[0026] FIG. 1 illustrates a mixing and delivery kit 30 employed for
obtaining an exemplary micronized allograft mixture 50 of the
present invention. Mixing and delivery kit 30 includes a mixing
syringe 35 and cap 39 (FIG. 2), a first needle 32 (which may be a
curved needle such as a curved delivery needle like a Tuohy
delivery needle) and a second needle 33 (which may be a straight
needle), and an obturator 34. A funnel 31 is also shown in FIG. 1
and may be optionally included as part of mixing and delivery kit
30. Mixing and delivery kit 30 may optionally include additional
needles, for example, additional straight and/or curved needles, to
aid in the delivery of the micronized allograft mixture 50 at the
defect site.
[0027] FIG. 2 illustrates an enlarged view of the special mixing
syringe 35 of the present invention which is employed for the
mixing/formation of micronized allograft mixture 50 (paste 50) of
the present invention. Syringe 35 is a modified conventional
syringe provided with a pushrod 37 that is designed and configured
to unsnap from (and snap back into) a mixing element 36 (mixing rod
36), to allow components that form micronized allograft mixture 50
to mix together and then to allow the formed mixture 50 to be
delivered at the surgical site (i.e., microfracture site which may
be part of any articular cartilage surface, for example, a knee, an
ankle, a foot, a shoulder, a hand, a wrist, an elbow, or a hip,
among others), as detailed below.
[0028] FIGS. 3-12 illustrate subsequent steps of an exemplary
technique of forming micronized allograft mixture 50 (paste 50)
which is part of delivery system 100 (FIGS. 9 and 12) of the
present invention.
[0029] FIG. 3: Remove the syringe cap 39 and snap on the funnel 31
to the end of the syringe 35. Make sure the plunger is at the end
of the syringe 35, then empty micronized allograft 20 (for example,
micronized cartilage 20) from its container into the funnel 31.
[0030] Micronized allograft 20 is preferably any micronized
cartilage with particles/particulates obtained by various methods,
for example, cartilage delivered in its native form, dehydrated via
lyophilization, "freeze-dried," dehydrated via desiccation, or
dehydrated by any other method. The size of the particles forming
the micronized allograft 20 may be of about 0-300 microns, to allow
the micronized particles to mix well with the autologous blood
product and form the resulting micronized allograft mixture 50
(paste 50).
[0031] In an exemplary-only embodiment, the micronized allograft 20
is BioCartilage.RTM., sold by Arthrex, Inc. (Naples, Fla.), which
consists essentially of allograft cartilage that has been
dehydrated and micronized. BioCartilage.RTM. contains the
extracellular matrix that is native to articular cartilage
including key components such as type II collagen, proteoglycans,
and additional cartilaginous growth factors. The principle of
BioCartilage.RTM. is to serve as a scaffold over a defect providing
a tissue network that can potentially signal autologous cellular
interactions and improve the degree and quality of tissue healing
within a properly prepared cartilage defect.
[0032] FIG. 4: Remove the funnel 31 and dispense an equivalent
amount of autologous blood solution 40 (from a second syringe or
container 45) as the micronized allograft 20 into the mixing
syringe 35 (about 1:1 ratio). Twist on the syringe cap and luer
cap.
[0033] FIG. 5: Unsnap (disengage) the pushrod 37 from the mixing
element 36 by pressing on the tip of the mixing element 36 with
counter pressure on the tip of the pushrod 37.
[0034] FIG. 6: To mix the micronized allograft 20 and autologous
blood solution 40, push and pull the mixing element 36 back and
forth while rotating it in a repeated left-to-right motion.
Continue until thoroughly mixed to form micronized allograft
mixture 50.
[0035] FIG. 7: Pull back the mixing element 36 to bring it back to
its starting position.
[0036] FIG. 8: Snap (engage) the pushrod 37 back onto the mixing
element 36.
[0037] FIG. 9: Apply either the straight needle 33 (for example, an
11-gauge straight needle) or the curved needle 32 (for example, a
Tuohy delivery needle) to form delivery system 100 and dispense the
micronized allograft mixture 50 out of the mixing syringe 35.
[0038] FIG. 10 illustrates an enlarged view of the special syringe
35 of the present invention with the pushrod 37
engaging/disengaging the mixing element 36 to allow mixing of the
micronized allograft tissue 20 with the autologous blood solution
40 in the syringe 35. FIG. 11 illustrates how a linear motion (back
and forth) and/or a rotating motion (left to right and/or
vice-versa) of the mixing element 36 facilitates the mixing of the
micronized allograft 20 with the autologous blood solution 40. FIG.
12 illustrates an enlarged view of the delivery system 100 of FIG.
9, showing part of the micronized allograft mixture 50 exiting
needle 32 attached to the special syringe 35.
[0039] FIGS. 13-16 illustrate yet another embodiment of mixing and
delivery system 100a (FIG. 15) wherein autologous blood solution 40
(from a syringe or container 45) is provided in contact with
micronized allograft 20 of container 21. The two components are
provided in about 1:1 ratio in open container 36 and mixed by hand
to obtain micronized allograft mixture 50a (paste 50a) shown in
FIGS. 14-16. A special dual syringe delivery system 35a may be
employed to provide/deliver the paste 50a to a microfracture site
(FIG. 15). Alternatively, the paste 50a may be delivered by the
surgeon to the surgical site using a hand, a dispenser, or any
sterile spatula.
[0040] FIGS. 17-22 illustrate a micronized cartilage knee surgical
technique according to an exemplary embodiment of the present
invention. FIGS. 17-22 illustrate femur 91, tibia 92 and surgical
site 90 containing an articular cartilage defect to be repaired
according to the present invention.
[0041] FIGS. 17 and 17(a): Debride the articular cartilage defect
90 to a stable border with about perpendicular margins. A scalpel
93 or cutting instrument 93 may be used to create the vertical
margins and a curette can be used to debride the calcified
cartilage layer at the base of the defect. When evaluating a
cartilage defect and preparing it, care must be taken to debride
the cartilage to a healthy cartilaginous border. In addition,
90.degree. margins should be created around the periphery of the
defect to help with containment of the product. The calcified
cartilage layer needs to be removed from the base of the defect
just like when performing a microfracture procedure (unlike the ACI
procedures).
[0042] FIG. 18: Perform bone marrow stimulation using standard
microfracture surgery to form several perforations in the
subchondral bone plate of microfracture site 88. A power pick 89
may be used to perform this procedure while applying irrigation
fluid to avoid thermal necrosis. The microfracture procedure is
performed through the subchondral plate which allows marrow
elements to incorporate into the implanted allograft material.
[0043] FIG. 19: Dry the defect thoroughly. The defect is dried with
gauze sponges or pledgets, for example, before implantation of the
allograft material.
[0044] Before implanting the allograft material 50, a drop or two
of fibrin adhesive can be applied to the corners of the base of the
defect to provide additional adhesive properties between the bone
bed and allograft material. It is preferred not to use fibrin
adhesive when possible, as to not occlude the microfracture holes
that were created.
[0045] The allograft cartilage 20 is micronized into particles with
a small enough size (of about 0-300 microns) so that when it is
mixed with a fluid such as an autologous blood product it has a
paste-like consistency that can be injected through a needle or
small cannula. The autologous blood product may be blood (whole
blood), autologous conditioned plasma, platelet-rich plasma, bone
marrow (for example, bone marrow concentrate or bone marrow
aspirate), stem cells (concentrated or expanded stem cells), or
combinations thereof. The allograft cartilage 20 can be provided in
a dehydrated state via a desiccation process or hypothermic
dehydration process instead of lyophilization of the material.
[0046] The micronized cartilage 20 is then mixed with an autologous
blood solution 40 (1:1 ratio) within the mixing syringe to form
micronized allograft mixture 50 (cartilage paste 50). After mixing
the micronized cartilage tissue 20 with the autologous blood
solution 40, the cartilage mixture 50 is applied at the defect 88
with exemplary delivery system 100.
[0047] As detailed above, the mixture of the allograft cartilage
with the autologous blood product may take place within a closed
mixing system to prevent the material from drying out when exposed
to air. This also helps to provide a very consistent and repeatable
mixture of the two products. The allograft/autologous blood product
is delivered to the defect directly for open procedures, or through
a needle or cannula for arthroscopic procedures.
[0048] As also detailed above, a straight needle or cannula may be
used to deliver the mixture. For example, the straight
needle/cannula can be inserted through the AM portal
arthroscopically for a medial femoral condyle defect. The
needle/cannula allows for delivery of the mixture directly into the
defect. Alternatively, a Tuohy style needle 32 (FIG. 19) or cannula
can also be used to deliver the mixture. For example, the Tuohy
style needle/cannula can be inserted through the AL portal
arthroscopically for a medial femoral condyle defect for cross
portal delivery of the mixture or it can be used in the same
fashion as the straight needle/cannula. The Tuohy shape is
particularly useful for the talar lesions of the ankle because it
allows for delivery into the defect much more easily than a
straight needle would be able to provide.
[0049] After delivery of the allograft/autologous blood product
mixture to the defect, the mixture is smoothed out over the defect
so that it is flush or slightly recessed in comparison to the
surrounding cartilage borders.
[0050] FIG. 20: Smooth out the cartilage mixture 50 within the
defect 88. Ensure that the cartilage mixture 50 is slightly
recessed when compared to the surrounding articular cartilage.
[0051] The mixture is compressed with manual pressure during open
procedures. For arthroscopic procedures, a tamp can be used to
provide compressive pressure directly, or an articulating elevator
can be used to provide compressive pressure from the cross portal
position when treating defects in the knee. For defects in the
talus (and as detailed below), an elevator can be used to provide
compression.
[0052] Alternatively, a metal template (which may be selected from
a plurality of metal templates that match the curvature of the
knee, similar to a uni-knee tamp) may be used to apply compression
against the defect evenly before a fibrin glue is applied and after
the fibrin glue sets up. This would help ensure the defect is
filled and shaped to match the curvature of the rest of the
condyle.
[0053] After compressing the mixture, additional amounts of the
mixture can be delivered and impacted until the final implant is
either flush or slightly recessed with respect to the surrounding
cartilage borders. After delivery of the implant, a fibrin adhesive
is applied over the top of the implant. The fibrin adhesive
provides a smooth barrier over the implanted material. The fibrin
adhesive is allowed to dry before deflating the tourniquet.
[0054] FIG. 21: Apply fibrin 51 over the top of the cartilage
mixture 50. Use enough to cover the defect, but prevent over-usage
as this will cause the construct to sit proud in the joint. Use of
a dual lumen applicator tip 53 is recommended to apply the fibrin
51 in order to prevent activation and clogging of the fibrin 51
within the needle. Do not manipulate for 5 minutes after
application. The knee may be gently ranged before closure to assure
cartilage mixture 50 adherence.
[0055] FIG. 22: At the completion of surgery and repair 200, a knee
immobilizer locked in extension is placed and the patient is made
non-weight bearing or protected weight bearing as determined by
defect location with delayed onset of range-of-motion for up to one
week postoperatively. Standard rehabilitation protocols used for
the tibiofemoral and patellofemoral joint may then be
implemented.
[0056] FIGS. 23-28 illustrate another exemplary embodiment of a
micronized cartilage knee arthrotomy surgical technique according
to the present invention:
[0057] FIGS. 23 and 23(a): Debride the articular defect to a stable
border with perpendicular margins. A Ring curette 94 and Cobb
elevator 95 can be used to create the vertical margins and debride
the calcified cartilage layer at the base of the defect 90.
[0058] FIG. 24: Perform bone marrow stimulation using a power pick
89 for microfracture formation to form microfracture site 88. After
microfracture, ensure the use of a tourniquet, aspirate the
arthroscopic fluid and dry the cartilage defect with pledgets.
[0059] FIG. 25: A Gemini cannula 96 is utilized in the portal that
resides over the defect 88. Apply distraction of the soft tissue
with the cannula 96 to improve visualization of the defect. The
cartilage mixture 50 can be applied over the defect 88 with a Tuohy
delivery needle 32 of delivery and mixing system 100.
[0060] FIG. 26: A paddle elevator 97 (for example, an articulating
paddle elevator 97) can be used to smooth out the cartilage mixture
50 within the defect so that it remains slightly recessed to the
surrounding cartilage.
[0061] FIG. 27: Apply a light layer of fibrin 51 over the cartilage
mixture 50 through a dual lumen applicator tip 53; prevent over
usage as this will cause the construct to sit proud. If a single
lumen needle/cannula is used, this will lead to premature
activation of the fibrin. Do not manipulate for 5 minutes after
application. The knee may be gently ranged before closure to assure
cartilage mixture 50 adherence and completion of surgery and final
repair 200a (FIG. 28).
[0062] FIGS. 29-34 illustrate an exemplary ankle arthroscopic
surgical technique according to another embodiment of the present
invention.
[0063] FIGS. 29 and 29(a): Under tourniquet control, apply about 4
mm of distraction to the tibiotalar joint 80. Debride the articular
cartilage defect to create stable margins. A Ring Curette 94 can be
used to create vertical margins and debride the base.
[0064] FIG. 30: Perform bone marrow stimulation utilizing a
microfracture awl 87 to form microfracture site 88. Aspirate all
arthroscopic fluid and dry the cartilage defect with pledgets.
[0065] FIG. 31: After mixing the micronized cartilage tissue 20
with an autologous blood solution 40 (1:1 ratio) within the mixing
syringe 35 to form cartilage mixture 50, apply the mixture 50 into
the defect 88 utilizing the Tuohy Delivery Needle 32.
[0066] FIG. 32: A Cobb Elevator 95 can be used to smooth out the
cartilage mixture 50 within the defect. Ensure that the cartilage
mixture 50 remains slightly recessed when compared to the
surrounding cartilage.
[0067] FIG. 33: Apply fibrin 51 over the cartilage mixture 50
through a dual lumen applicator tip 53. Avoid applying too much
fibrin 51 to prevent the construct from sitting proud.
[0068] FIG. 34: At the completion of surgery, the ankle is
immobilized in neutral position and the patient is made non-weight
bearing. Standard rehabilitation protocols following microfracture
surgery may then be implemented.
[0069] The micronized cartilage mixture 50, 50a of the present
invention may optionally comprise additional components such as
proteins, growth factors or chemicals that may be provided within
the mixtures. The autologous blood product may be blood (whole
blood), plasma, autologous conditioned plasma, platelet-rich
plasma, bone marrow, bone marrow aspirate, bone marrow concentrate,
stem cells such as concentrated or expanded stem cells (derived
from a variety of sources), or any combinations of these
products.
[0070] In accordance with exemplary-only embodiments, the mixtures
may be obtained to additionally comprise components such as growth
factors, additional antiseptic chemicals and/or antibiotics and/or
electrolytes, or hormones or site-specific hybrid proteins (that
promote or enhance the wound healing effectiveness of the growth
factors), or glue such as fibrin glue and/or adhesives, among
others.
[0071] Although the present invention has been described in
connection with preferred embodiments, many modifications and
variations will become apparent to those skilled in the art. While
preferred embodiments of the invention have been described and
illustrated above, it should be understood that these are exemplary
of the invention and are not to be considered as limiting.
* * * * *